ZA833845B - Microbiological process - Google Patents

Microbiological process

Info

Publication number
ZA833845B
ZA833845B ZA833845A ZA833845A ZA833845B ZA 833845 B ZA833845 B ZA 833845B ZA 833845 A ZA833845 A ZA 833845A ZA 833845 A ZA833845 A ZA 833845A ZA 833845 B ZA833845 B ZA 833845B
Authority
ZA
South Africa
Prior art keywords
alpha interferon
microbiological process
gene
taught
expressed
Prior art date
Application number
ZA833845A
Other languages
English (en)
Inventor
Eva Dworkin-Rastl
Marc-Bruce Dworkin
Guenther Adolf
Peter Meindl
Gerhard Bodo
Peter Swetly
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6164725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA833845(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of ZA833845B publication Critical patent/ZA833845B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA833845A 1982-05-28 1983-05-27 Microbiological process ZA833845B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823220116 DE3220116A1 (de) 1982-05-28 1982-05-28 Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
ZA833845B true ZA833845B (en) 1985-01-30

Family

ID=6164725

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA833845A ZA833845B (en) 1982-05-28 1983-05-27 Microbiological process

Country Status (22)

Country Link
US (1) US4820638A (sv)
EP (1) EP0095702B1 (sv)
JP (2) JPH0774238B2 (sv)
KR (1) KR920006349B1 (sv)
AT (1) ATE42114T1 (sv)
AU (1) AU565479B2 (sv)
DD (1) DD211359C4 (sv)
DE (2) DE3220116A1 (sv)
DK (1) DK164742C (sv)
ES (2) ES8403522A1 (sv)
FI (1) FI82072C (sv)
GR (1) GR79236B (sv)
HK (1) HK112893A (sv)
HU (1) HU196452B (sv)
IL (1) IL68790A (sv)
MX (1) MX9202815A (sv)
NO (1) NO168538C (sv)
NZ (1) NZ204384A (sv)
SG (1) SG38692G (sv)
SU (1) SU1346048A3 (sv)
UA (1) UA8037A1 (sv)
ZA (1) ZA833845B (sv)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
US4709324A (en) * 1985-11-27 1987-11-24 Motorola, Inc. Data processor control unit having an interrupt service using instruction prefetch redirection
CA2025180A1 (en) * 1989-10-12 1991-04-13 William G. Weisburg Nucleic acid probes and methods for detecting pathogenic candida yeasts
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
KR20040007413A (ko) * 2000-11-03 2004-01-24 바이오메디신즈 인코포레이티드 단기 및 장기 약물 약량측정 방법
FR2817559B1 (fr) * 2000-12-06 2003-12-12 Genodyssee Procede de determination d'un ou plusieurs polymorphisme(s) fontionnel(s) dans la sequence nucleique d'un gene "candidat" fonctionnel preselectionne et ses applications
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
CN100438870C (zh) * 2001-11-09 2008-12-03 精达制药公司 ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US8906676B2 (en) * 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906160A1 (de) * 1979-02-17 1980-09-04 Thomae Gmbh Dr K Verbessertes verfahren zur herstellung von humaninterferon
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
ES8308534A1 (es) * 1980-01-08 1983-09-01 Biogen Nv Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
DE3005843A1 (de) * 1980-02-16 1981-09-10 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
DE3106982A1 (de) * 1981-02-25 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach "neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
IL63327A (en) * 1981-07-16 1985-11-29 Yeda Res & Dev Production of interferon beta1 and alpha-phage recombinants for its production in host bacteria
GB2108510B (en) 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof

Also Published As

Publication number Publication date
DK164742B (da) 1992-08-10
DK164742C (da) 1992-12-28
ES8500321A1 (es) 1984-10-01
KR840004944A (ko) 1984-10-31
NO831903L (no) 1983-11-29
DE3220116A1 (de) 1983-12-01
JPH0774238B2 (ja) 1995-08-09
NO168538B (no) 1991-11-25
EP0095702A1 (de) 1983-12-07
MX9202815A (es) 1992-06-30
SU1346048A3 (ru) 1987-10-15
HU196452B (en) 1988-11-28
HK112893A (en) 1993-10-29
FI831818L (fi) 1983-11-29
ES522762A0 (es) 1984-03-16
KR920006349B1 (ko) 1992-08-03
ATE42114T1 (de) 1989-04-15
DK239383A (da) 1983-11-29
DD211359C4 (de) 1986-09-24
DE3220116C2 (sv) 1993-02-18
DD211359A5 (de) 1984-07-11
EP0095702B1 (de) 1989-04-12
FI831818A0 (fi) 1983-05-23
IL68790A0 (en) 1983-09-30
JPS5925689A (ja) 1984-02-09
ES529360A0 (es) 1984-10-01
IL68790A (en) 1991-06-10
JP2558422B2 (ja) 1996-11-27
NZ204384A (en) 1986-11-12
ES8403522A1 (es) 1984-03-16
NO168538C (no) 1992-03-04
FI82072C (sv) 1991-01-10
AU1504483A (en) 1983-12-01
DE3379591D1 (en) 1989-05-18
SG38692G (en) 1992-09-04
US4820638A (en) 1989-04-11
GR79236B (sv) 1984-10-22
AU565479B2 (en) 1987-09-17
DK239383D0 (da) 1983-05-27
JPH0678774A (ja) 1994-03-22
UA8037A1 (uk) 1995-12-26
FI82072B (fi) 1990-09-28

Similar Documents

Publication Publication Date Title
ZA833845B (en) Microbiological process
GB8610600D0 (en) Transformation of trichoderma
GR3003691T3 (sv)
ES8708236A1 (es) Un metodo para eliminar la metionina n-terminal de una metionil-proteina
GB8414354D0 (en) Purifying protein
DE3569112D1 (en) 4,5-dihydro-4-oxo-2- û(2-trans-phenylcyclopropyl)amino¨-3-furancarboxylic acids and derivatives thereof
ATE50597T1 (de) Alpha-interferon gx-1.
EP0180737A3 (en) Use of preparations containing gamma-interferon (ifn-gamma) for treating rheumatic diseases
AU590712B2 (en) Immune interferon and method for its purification
JPS5775960A (en) Purified polypeptide
CS160983A2 (en) Method of polypetide production with sequence of animal interferon's amino acids